ERCC基因多态性与骨肉瘤的生存相关性

张晋煜; 彭灼辉

ERCC基因多态性与骨肉瘤的生存相关性

昆明医科大学第三附属医院云南省肿瘤医院骨科

基金项目:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (20147FZ038);

计量
- 文章访问数: 2515
- HTML全文浏览量: 885
- PDF下载量: 74
- 被引次数: 3
出版历程
- 收稿日期: 2017-04-21

Relationship between Single Nucleotide Polymorphisms of ERCC Gene and Survival of Osteosarcoma

Funds:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (20147FZ038);

摘要

摘要: 目的探讨骨肉瘤患者及正常人群 (excision repair cross-complementing, ERCC) 基因ERCC1Asn118Asn (rs11615) 和ERCC1 Gln504Lys (rs3212986) , ERCC2Asp312Asn (rs1799793) 和ERCC2Lys751Gln (rs13181) 单核苷酸多态性与骨肉瘤患者对顺铂的反应和生存状况的关系.方法 2011年1月至2015年12月住院收治的骨肉瘤患者161例及正常人群163例, 静脉血2 m L, 用实时逆转录聚合酶链式反应方法 (real time quantitative polymerase chain reaction, RT-PCR) 比较骨肉瘤患者及正常人群ERCC1Asn118Asn (rs11615) 和ERCC1 Gln504Lys (rs3212986) , ERCC2Asp312Asn (rs1799793) 和ERCC2 Lys751Gln (rs13181) 基因型及等位基因分布频率.对骨肉瘤患者按不同的临床因素 (年龄、性别、病理类型、肿瘤部位、Enneking外科分期、肿瘤转移及治疗方法) 进行分组, 比较各组基因型频率及等位基因频率, 分析基因多态性与各临床因素的关系.结果 (1) ERCC1Asn118Asn (rs11615) 和ERCC1 Gln504Lys (rs3212986) , ERCC2Asp312Asn (rs1799793) 和ERCC2Lys751Gln (rs13181) 基因型有CC、CT、TT型, 骨肉瘤患者及正常人群基因型频率 (CC、CT、TT) 及等位基因频率 (C、T) 比较差异均无统计学意义 (P=0.590, P=0.544) ; (2) 对于ERCC1 Asn118Asn, 与野生型C/C相比, 突变型T/T与较高的无病生存率显著相关, 校正OR值 (95%CI) 0.37 (0.150.85) .ERCC2 751 A/A基因型表现为骨肉瘤患者生存率增加 (HR=0.45, 95%CI 0.110.88) .没有证明ERCC1 Gln504Lys与ERCC2Asp312Asn的多态性和骨肉瘤预后相关.结论 ERCC基因ERCC1 Asn118Asn118T/T和ERCC2 Lys751Gln A/A多态性与骨肉瘤无病生存率 (SFS) 相关, 可以用作顺铂治疗的骨肉瘤患者临床预后的标志物.而ERCC1 Gln504Lys (rs3212986) 、ERCC2 Asp312Asn与骨肉瘤无病生存率 (SFS) 无相关性.
- 骨肉瘤 /
- ERCC1 /
- ERCC2 /
- 多态性 /
- 单核苷酸 /
- 生存率
Abstract: Objective To study the relationship between single nucleotide polymorphisms (SNPs) of ERCC1 Asn118 Asn (rs11615) , ERCC1 Gln504 Lys (rs3212986) , ERCC2 Asp312 Asn (rs1799793) and ERCC2 Lys751 Gln (rs13181) and osteosarcoma survival with the osteosarcoma patients.Methods 161 patients with osteosarcoma in our hospital from January 2010 to Decemher 2015 and 163 heahhy adults were enrolled in this study.2 m L peripheral blood samples were taken from each person.The RT-q PCR method was used to detect the genotype and allele frequency distribution of ERCC1 Asn118 Asn (rs11615) , ERCC1 Gln504 Lys (rs3212986) , ERCC2 Asp312 Asn (rs1799793) and ERCC2 Lys751 Gln (rs13181) in osteosarcoma patients and normal population.Osteosarcoma patients were divided into several groups according to the clinical parameters such as age, gender, histology, tumor location, Enneking classification, tumormetastasis and therapy, and analyzed the relations between the genetic polymorphism and clinical parameters.Results For ERCC1 Asn118 Asn, thevariant genotype T/T was strongly significantly associated with a higher disease-free survival when compared with the wild-type C/C, with an adjusted OR (95% CI) of 0.37 (0.15-0.85) .ERCC2 751 A/A genotype showed increased disease-free survival of osteosarcoma (HR=0.45; 95% CI=0.11-0.88) .However, we did not find significant association of ERCC1 Gln504 Lys and ERCC2 Asp312 Asn polymorphisms with prognosis of osteosarcoma.Conclusions The genetic polymorphism of ERCC gene at ERCC1 Asn118 Asn T/T, ERCC2 Lys751 Gln A/A is associated with osteosarcoma disease-free survival (SFS) , can be used as clinical prognostic markers for osteosarcoma patients with cisplatin treatment.But ERCC1 Gln504 Lys (rs3212986) , ERCC2 Asp312 Asn have no correlation with osteosarcoma disease-free survival (SFS) .
- Osteosarcoma /
- ERCC1 /
- ERCC2 /
- Polymorphism /
- Survival /
- Cisplain treatment

HTML全文

参考文献(11)

[1]	[1]BO CHEN, YONG ZHOU, PING YANG.ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk:a meta-analysis[J].J Cancer Res Clin, 2011, 137 (6) :939-946.[1]BO CHEN, YONG ZHOU, PING YANG.ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk:a meta-analysis[J].J Cancer Res Clin, 2011, 137 (6) :939-946.
[2]	[2]ISHIBASHI K, OKADA N, TAJIMA Y, et al.Prediction of theefficacy of modified FOLFOX6 therapy according to them RNA levels of thymidylate synthase (TS) , excision repaircross-complementing-1 and-2 (ERCC-1 and ERCC-2) andmethylenetetrahydrofolate dehydrogenase (MTHFD) in theprimary lesion of colorectal cancer[J].Gan To Kagaku Ryoho, 2011, 38 (12) :2220-2223.[2]ISHIBASHI K, OKADA N, TAJIMA Y, et al.Prediction of theefficacy of modified FOLFOX6 therapy according to them RNA levels of thymidylate synthase (TS) , excision repaircross-complementing-1 and-2 (ERCC-1 and ERCC-2) andmethylenetetrahydrofolate dehydrogenase (MTHFD) in theprimary lesion of colorectal cancer[J].Gan To Kagaku Ryoho, 2011, 38 (12) :2220-2223.
[3]	[3]CAO C, ZHANG Y M, WANG R, et al.Excision repair crosscomplementation group 1 polymorphisms and lung cancerrisk:a meta-analysis[J].Chin Med J (Engl) , 2011, 124 (14) :2203-2208.[3]CAO C, ZHANG Y M, WANG R, et al.Excision repair crosscomplementation group 1 polymorphisms and lung cancerrisk:a meta-analysis[J].Chin Med J (Engl) , 2011, 124 (14) :2203-2208.
[4]	[4]LU X F, YANG W L, WAN Z H, et al.Glutathione S-transferasepolymorphisms and bone tumor risk in China[J].Asian Pac JCancer Prev, 2011, 12 (12) :3357-3360.[4]LU X F, YANG W L, WAN Z H, et al.Glutathione S-transferasepolymorphisms and bone tumor risk in China[J].Asian Pac JCancer Prev, 2011, 12 (12) :3357-3360.
[5]	[5]ROUISSI K, BAHRIA I B, BOUGATEF K, et al.The effect otobacco, XPC, ERCC2 and ERCC5 genetic variants inbladder cancer development[J].BMC Cancer, 2011, 11 (1) :101.[5]ROUISSI K, BAHRIA I B, BOUGATEF K, et al.The effect otobacco, XPC, ERCC2 and ERCC5 genetic variants inbladder cancer development[J].BMC Cancer, 2011, 11 (1) :101.
[6]	[6]CARONIA D, PATINO-GARCIA A, MILNE R L, et al.Commonvariations in ERCC2 are associated with response to cisplatinchemotherapy and clinical outcome in osteosarcomapatients[J].Pharmacogenomics J, 2009, 9 (5) :347-353.[6]CARONIA D, PATINO-GARCIA A, MILNE R L, et al.Commonvariations in ERCC2 are associated with response to cisplatinchemotherapy and clinical outcome in osteosarcomapatients[J].Pharmacogenomics J, 2009, 9 (5) :347-353.
[7]	[7]ENNEKING W F, DANHAM W, GEBHAMDT M C, et al.A system for the functional evaluation of reconstruction procedures after surgical treatment of tumors of the musculo skeletal systeme[J].Clin Orthop, 1993, 286:241-246.[7]ENNEKING W F, DANHAM W, GEBHAMDT M C, et al.A system for the functional evaluation of reconstruction procedures after surgical treatment of tumors of the musculo skeletal systeme[J].Clin Orthop, 1993, 286:241-246.
[8]	[8]RYUJ S, HONG Y C, HAN H S, et al.Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer, 2004, 44 (3) :311-316.[8]RYUJ S, HONG Y C, HAN H S, et al.Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer, 2004, 44 (3) :311-316.
[9]	[9]CHO E Y, HIDESHEIM A, CHEN C J, et al.Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and h OGG1[J].Cancer Epidemiol Biomarkers Prev, 2003, 12 (10) :1100-1104.[9]CHO E Y, HIDESHEIM A, CHEN C J, et al.Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and h OGG1[J].Cancer Epidemiol Biomarkers Prev, 2003, 12 (10) :1100-1104.
[10]	[10]XING D, TAN W, LIN D.Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population[J].Oncol Rep, 2003, 10 (5) :1615-1623.[10]XING D, TAN W, LIN D.Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population[J].Oncol Rep, 2003, 10 (5) :1615-1623.
[11]	[11]SUN J M, AHN M J, PARK M J, et al.Expression of excisionrepair cross-complementation group 1 as predictivemarker for nasopharyngeal cancer treated with concurrentchemoradiotherapy[J].Int J Radiat Oncol Biol Phys, 2011, 80 (3) :655-660.[11]SUN J M, AHN M J, PARK M J, et al.Expression of excisionrepair cross-complementation group 1 as predictivemarker for nasopharyngeal cancer treated with concurrentchemoradiotherapy[J].Int J Radiat Oncol Biol Phys, 2011, 80 (3) :655-660.

相关文章(20)

[1]	马彬斌, 张少雄, 高永丽. 基于生物信息学探究ESCRT相关基因对骨肉瘤预后的评估价值, 昆明医科大学学报.
[2]	李博一, 牛玲, 马蓉, 张娴, 刘方, 唐艳, 苗翠娟, 张程, 韩竺君. 护骨素基因启动子区T950C多态性与2型糖尿病合并骨质疏松症的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220306
[3]	赵云欣, 孟繁媛, 刘巍, 吴会东, 罗长良, 李彬, 敖丽娟, 陈茉弦. 单核苷酸多态性与青少年特发性脊柱侧凸的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221121
[4]	周灵, 胡凤娣, 李蓉, 廖冶丹, 耿证琴, 唐嘉黛, 张雪琪, 谢琳, 杨祚璋. 预测骨肉瘤化疗耐药的临床评分系统, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210144
[5]	徐海霞, 李心红. 蒙古族人MicroRNA-149和196a2单核苷酸多态性肝细胞癌易感性, 昆明医科大学学报.
[6]	李珊珊, 全宇航, 龚玲俐, 杨会, 浦劲宏, 王忠慧. 七氟烷对人骨肉瘤Saos2细胞增殖、侵袭、迁移及凋亡的影响, 昆明医科大学学报.
[7]	念馨. 金属硫蛋白基因G-201A多态性在2型糖尿病及原发性高血压的分布差异性, 昆明医科大学学报.
[8]	李盈甫. ARL 15基因rs4311394多态性与非小细胞肺癌遗传易感性的关联, 昆明医科大学学报.
[9]	李会芳. 糖尿病肾病易感基因位点多态性的交互作用, 昆明医科大学学报.
[10]	张磊. 287例直肠癌术后预后因素的回顾性分析, 昆明医科大学学报.
[11]	陆斌. 骨肉瘤患者血浆中microRNA-181b水平的检测, 昆明医科大学学报.
[12]	安新焕. ACE和eNOS 2个基因多态性并存与糖尿病肾病的相关性, 昆明医科大学学报.
[13]	兰丹凤. Klotho基因G-395A多态性与2型糖尿病患者并发动脉粥样硬化的相关性, 昆明医科大学学报.
[14]	邓德耀. PGC-1α基因Gly482Ser多态性与2型糖尿病的相关性研究, 昆明医科大学学报.
[15]	李盈甫. 脂联素基因多态性与非小细胞肺癌遗传易感性的关联, 昆明医科大学学报.
[16]	陈灿. MDS1-EVI1基因多态性与鼻咽癌相关性研究, 昆明医科大学学报.
[17]	李会芳. 佤族人群CCR5基因59029G/A多态性与糖尿病前期和糖尿病的相关性研究, 昆明医科大学学报.
[18]	陈瑞彬. ERCC1反义寡核苷酸对肺癌铂类药物敏感性的研究进展, 昆明医科大学学报.
[19]	念馨. 2型糖尿病FOXC2基因C-1702T多态性与血清总胆固醇相关性, 昆明医科大学学报.
[20]	. 肌层浸润性膀胱癌的治疗策略, 昆明医科大学学报.